Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Pramlintide.

Research draft

Pramlintide is a synthetic amylin analogue used as an adjunct in diabetes care.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Pramlintide is a synthetic amylin analogue used as an adjunct in diabetes care.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It affects meal-related glucagon secretion, gastric emptying and satiety.

Human research

Clinical evidence supports a specific diabetes context; it cannot validate unrelated self-directed weight-loss use.

Preclinical & other research

Physiological studies clarify its complementary action to insulin.

Safety & unknowns

Nausea and severe hypoglycaemia when used with insulin are central concerns.

Regulatory status

US Symlin is an approved prescription product with defined eligibility and warnings.

Reported use & evidence

Research profile draft

The supplied Pramlintide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds